An Open-Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017

Trial Profile

An Open-Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Peginterferon beta-1a (Primary) ; Naproxen
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms ALLOW
  • Sponsors Biogen
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Apr 2017 Results of treatment satisfaction questionnaire for medication (n=194) presented at the 69th Annual Meeting of the American Academy of Neurology
    • 04 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top